The GLP-1 Gap: Disparities in Adolescent Weight Management
A retrospective cohort study published in *Pediatrics* examined the real-world use of GLP-1 receptor agonists (GLP-1RAs) in a pediatric weight management clinic. Analyzing data from 1,647 adolescents with severe obesity, researchers found that only 20% received a prescription for these medications. Prescriptions were significantly more likely for older patients, those with higher BMI, and those with abnormal metabolic lab results. The study also revealed concerning disparities: non-Hispanic Black youth and those whose preferred language was not English were less likely to be prescribed a GLP-1RA, even after accounting for clinical factors. Furthermore, among those who did get a prescription, nearly two-thirds experienced treatment interruptions, primarily due to insurance denials and high out-of-pocket costs.
Why it might matter to you: This research highlights a critical implementation gap in pediatric obesity care, where effective pharmacotherapy is not reaching many eligible patients. For clinicians, it underscores the need to audit prescribing patterns for potential bias and to develop systematic approaches for discussing all treatment options equitably. The high rate of post-prescription barriers, mainly financial, points to a systemic challenge that requires advocacy for better insurance coverage and patient support programs to ensure sustained treatment.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
